Models of care for the management of hepatitis C virus among people who inject drugs: One size does not fit all

Philip Bruggmann, Alain H. Litwin

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

One of the major obstacles to hepatitis C virus (HCV) care in people who inject drugs (PWID) is the lack of treatment settings that are suitably adapted for the needs of this vulnerable population. Nevertheless, HCV treatment has been delivered successfully to PWID through various multidisciplinary models such as community-based clinics, substance abuse treatment clinics, and specialized hospital-based clinics. Models may be integrated in primary care - all under one roof in either addiction care units or general practitioner-based models - or can occur in secondary or tertiary care settings. Additional innovative models include directly observed therapy and peer-based models. A high level of acceptance of the individual life circumstances of PWID rather than rigid exclusion criteria will determine the level of success of any model of HCV management. The impact of highly potent and well-tolerated interferon-free HCV treatment regimens will remain negligible as long as access to therapy cannot be expanded to the most affected risk groups.

Original languageEnglish (US)
JournalClinical Infectious Diseases
Volume57
Issue numberSUPPL.2
DOIs
StatePublished - 2013

Fingerprint

Hepacivirus
Pharmaceutical Preparations
Directly Observed Therapy
Therapeutics
Secondary Care
Vulnerable Populations
Tertiary Healthcare
General Practitioners
Interferons
Substance-Related Disorders
Primary Health Care

Keywords

  • Hepatitis C
  • IDU
  • Integrated care
  • Management
  • People who inject drugs

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)

Cite this

Models of care for the management of hepatitis C virus among people who inject drugs : One size does not fit all. / Bruggmann, Philip; Litwin, Alain H.

In: Clinical Infectious Diseases, Vol. 57, No. SUPPL.2, 2013.

Research output: Contribution to journalArticle

@article{f9a77c9ecad5469ab590dfd221192d8a,
title = "Models of care for the management of hepatitis C virus among people who inject drugs: One size does not fit all",
abstract = "One of the major obstacles to hepatitis C virus (HCV) care in people who inject drugs (PWID) is the lack of treatment settings that are suitably adapted for the needs of this vulnerable population. Nevertheless, HCV treatment has been delivered successfully to PWID through various multidisciplinary models such as community-based clinics, substance abuse treatment clinics, and specialized hospital-based clinics. Models may be integrated in primary care - all under one roof in either addiction care units or general practitioner-based models - or can occur in secondary or tertiary care settings. Additional innovative models include directly observed therapy and peer-based models. A high level of acceptance of the individual life circumstances of PWID rather than rigid exclusion criteria will determine the level of success of any model of HCV management. The impact of highly potent and well-tolerated interferon-free HCV treatment regimens will remain negligible as long as access to therapy cannot be expanded to the most affected risk groups.",
keywords = "Hepatitis C, IDU, Integrated care, Management, People who inject drugs",
author = "Philip Bruggmann and Litwin, {Alain H.}",
year = "2013",
doi = "10.1093/cid/cit271",
language = "English (US)",
volume = "57",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "SUPPL.2",

}

TY - JOUR

T1 - Models of care for the management of hepatitis C virus among people who inject drugs

T2 - One size does not fit all

AU - Bruggmann, Philip

AU - Litwin, Alain H.

PY - 2013

Y1 - 2013

N2 - One of the major obstacles to hepatitis C virus (HCV) care in people who inject drugs (PWID) is the lack of treatment settings that are suitably adapted for the needs of this vulnerable population. Nevertheless, HCV treatment has been delivered successfully to PWID through various multidisciplinary models such as community-based clinics, substance abuse treatment clinics, and specialized hospital-based clinics. Models may be integrated in primary care - all under one roof in either addiction care units or general practitioner-based models - or can occur in secondary or tertiary care settings. Additional innovative models include directly observed therapy and peer-based models. A high level of acceptance of the individual life circumstances of PWID rather than rigid exclusion criteria will determine the level of success of any model of HCV management. The impact of highly potent and well-tolerated interferon-free HCV treatment regimens will remain negligible as long as access to therapy cannot be expanded to the most affected risk groups.

AB - One of the major obstacles to hepatitis C virus (HCV) care in people who inject drugs (PWID) is the lack of treatment settings that are suitably adapted for the needs of this vulnerable population. Nevertheless, HCV treatment has been delivered successfully to PWID through various multidisciplinary models such as community-based clinics, substance abuse treatment clinics, and specialized hospital-based clinics. Models may be integrated in primary care - all under one roof in either addiction care units or general practitioner-based models - or can occur in secondary or tertiary care settings. Additional innovative models include directly observed therapy and peer-based models. A high level of acceptance of the individual life circumstances of PWID rather than rigid exclusion criteria will determine the level of success of any model of HCV management. The impact of highly potent and well-tolerated interferon-free HCV treatment regimens will remain negligible as long as access to therapy cannot be expanded to the most affected risk groups.

KW - Hepatitis C

KW - IDU

KW - Integrated care

KW - Management

KW - People who inject drugs

UR - http://www.scopus.com/inward/record.url?scp=84881004592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881004592&partnerID=8YFLogxK

U2 - 10.1093/cid/cit271

DO - 10.1093/cid/cit271

M3 - Article

C2 - 23884067

AN - SCOPUS:84881004592

VL - 57

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - SUPPL.2

ER -